Advanced Search
MyIDEAS: Login

Explaining Pharmaceutical R&D Growth Rates at the Industry Level: New Perspectives and Insights

Contents:

Author Info

  • Giaccotto, Carmelo
  • Santerre, Rexford
  • Vernon, John

Abstract

This paper uses aggregate data for the major pharmaceutical companies in the U.S. to study the rate of growth in pharmaceutical R&D intensity over the period from 1952 to 2001. The theoretical model argues and the empirical findings suggest that pharmaceutical R&D spending increases with real drug prices, after holding constant other determinants of R&D. Simulations based on our multiple regression model indicate that the capitalized value of pharmaceutical R&D spending would have been about 30 percent lower if the federal government had limited the rate of growth in drug price increases to the rate of growth in the general consumer price index during the period 1980 to 2001. Moreover, a drug price control regime would have resulted in 330 to 365 fewer new drugs brought to the global market during that same time period.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://regulation2point0.org/wp-content/plugins/download-monitor/download.php?id=388
Download Restriction: no

Bibliographic Info

Paper provided by Regulation2point0 in its series Working paper with number 388.

as in new window
Length:
Date of creation: Dec 2003
Date of revision:
Handle: RePEc:reg:wpaper:388

Contact details of provider:
Web page: http://regulation2point0.org/

Related research

Keywords:

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as in new window

Cited by:
  1. Corinne Sauer & Robert Sauer, 2007. "Is it possible to have cheaper drugs and preserve the incentive to innovate? The benefits of privatizing the drug approval process," The Journal of Technology Transfer, Springer, vol. 32(5), pages 509-524, October.
  2. Rexford Santerre & John A. Vernon, 2005. "Assessing Consumer Gains from a Drug Price Control Policy in the U.S," NBER Working Papers 11139, National Bureau of Economic Research, Inc.

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:reg:wpaper:388. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Archive Maintainer).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.